Last reviewed · How we verify
NCT07182916: FRASC
Factors Associated With Early Readmission in Critical Care
trial testing No intervention in Early Readmission to the ICU in 1,000 participants. Currently enrolling.
15 April 2026
Quick facts
| Lead sponsor | Société Française d'Anesthésie et de Réanimation |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 12 January 2026 |
| Primary completion | 15 April 2026 |
| Estimated completion | 15 June 2026 |
| Sites | 1 location across France |
Drugs / interventions tested
- No intervention
Conditions studied
- Early Readmission to the ICU — all drugs for Early Readmission to the ICU →
Sponsor
Société Française d'Anesthésie et de Réanimation
Who can join
18 and older, any sex, with Early Readmission to the ICU. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The COVID-19 health crisis has highlighted pre-existing challenges in patient flow management within healthcare facilities, especially in critical care units. This has sparked debate regarding the sufficiency of critical care beds in France, while drawing attention to the lack of downstream structures. Inefficient patient flow, leading to bed occupancy bottlenecks, has been correlated with both critical care length of stay and morbidity. Unplanned early readmission to critical care further exacerbates these strains and prolongs hospital length of stay. Currently, no standardized criteria are available to guide safe discharge from critical care. A recent Delphi consensus study proposed a set of criteria, although largely subjective. The primary outcome of the present study is to identify factors associated with unplanned early readmission to critical care within 48 hours of discharge. Delayed discharge from critical care represents another major bottleneck contributing to system strain. The secondary outcome of this study is therefore to assess the proportion of critical care beds occupied by patients deemed ready for discharge by the medical team, as well as to analyze the reasons underlying such delayed transfers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07182916
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other Société Française d'Anesthésie et de Réanimation trials
Trials by the same sponsor.
- NCT07526220 — Prognostic Factors in Critically Ill Patients Admitted After Caustic Ingestion in France · not yet recruiting
- NCT07317635 — Impact of Implementing a National Classification of Surgical Emergencies on Postoperative Morbidity and Mortality: a Pro · not yet recruiting
- NCT06768515 — ICU Management of Brain-Dead Donors Before Multi-Organ Procurement and Factors Associated With the Number of Organs Retr · recruiting
- NCT06257407 — Perioperative Hemostasis Management in Liver Transplantation · recruiting
- NCT06487442 — Management of Postoperative Pain in France: a Prospective National Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07182916 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Société Française d'Anesthésie et de Réanimation
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07182916.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing